Suppr超能文献

选择性组蛋白去乙酰化酶 6 抑制剂的开发和治疗意义。

Development and therapeutic implications of selective histone deacetylase 6 inhibitors.

机构信息

Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Illinois 60612, United States.

出版信息

J Med Chem. 2013 Aug 22;56(16):6297-313. doi: 10.1021/jm4001659. Epub 2013 May 15.

Abstract

This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated. The physiological pathways, protein-protein interactions, and non-histone substrates relating to different pathological conditions are discussed with regard to HDAC6. Furthermore, the compounds and methods used to modulate HDAC6 activity are profiled. The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the molecular tools available. Potential obstacles and future directions of HDAC6 research are also presented.

摘要

这篇观点文章深入探讨了组蛋白去乙酰化酶 6(HDAC6)涉及的众多疾病状态。讨论了与不同病理条件相关的生理途径、蛋白质-蛋白质相互作用和非组蛋白底物与 HDAC6 的关系。此外,还介绍了用于调节 HDAC6 活性的化合物和方法。本观点文章的后半部分根据结构、对其他 HDAC 同工酶的效力和选择性分析了报道的 HDAC6 选择性抑制剂,旨在全面概述现有的分子工具。还提出了 HDAC6 研究的潜在障碍和未来方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验